Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes.
about
Endothelial Dysfunction: Clinical Implications in Cardiovascular Disease and Therapeutic ApproachesNitric oxide synthases: regulation and functionReduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats.Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 ratVascular endothelial function and hypertension: insights and directionsDepletion of endothelial or smooth muscle cell-specific angiotensin II type 1a receptors does not influence aortic aneurysms or atherosclerosis in LDL receptor deficient mice.Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors.Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials.Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling.Comparative effects of different modes of renin angiotensin system inhibition on hypercholesterolaemia-induced atherosclerosis.Dahl salt-sensitive rats are protected against vascular defects related to diet-induced obesityDifferential effects of dietary sodium intake on blood pressure and atherosclerosis in hypercholesterolemic mice.Augmentation of the renin-angiotensin system by hypercholesterolemia promotes vascular diseases.The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studiesAliskiren Inhibits Neointimal Matrix Metalloproteinases in Experimental Atherosclerosis.Managing cardiovascular and renal risk: the potential of direct renin inhibition.Aliskiren improves vascular smooth muscle function in the skin microcirculation of type 2 diabetic patients with normal renal functionDirect renin inhibition with aliskiren protects against myocardial ischemia/reperfusion injury by activating nitric oxide synthase signaling in spontaneously hypertensive rats.Induction of microRNA-138 by pro-inflammatory cytokines causes endothelial cell dysfunction.Is there a future for direct renin inhibitors?Unmet needs in managing hypertension: potential role of direct renin inhibition.Aliskiren: beyond blood pressure reduction.New class of agents for treatment of hypertension: focus on direct renin inhibition.Direct renin inhibition: update on clinical investigations with aliskiren.Reducing cardiovascular events and end-organ damage in patients with hypertension: new considerations.Roles of the WHHL rabbit in translational research on hypercholesterolemia and cardiovascular diseases.Nitric oxide: orchestrator of endothelium-dependent responses.Is tetrahydrobiopterin a therapeutic option in diabetic hypertensive patients?Aliskiren as a novel therapeutic agent for hypertension and cardio-renal diseases.Oral renin inhibitors in clinical practice: a perspective reviewRedox-sensitive mechanisms underlying vascular dysfunction in heart failure.Endothelial cell dysfunction as a novel therapeutic target in atherosclerosis.Aliskiren improves endothelium-dependent relaxation of thoracic aorta by activating PI3K/Akt/eNOS signal pathway in SHR.Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inflammation and by increasing the phosphorylation ratio Ser(1177)/Thr(497) of endothelial nitric oxide synthase in diabetic mice.Effect of aliskiren, telmisartan and torsemide on cardiac dysfunction in l-nitro arginine methyl ester (l-NAME) induced hypertension in rats.Differential effects of aliskiren/amlodipine combination and high-dose amlodipine monotherapy on endothelial function in elderly hypertensive patients.MRI assessment of coronary microvascular endothelial nitric oxide synthase function using myocardial T1 mapping.Aliskiren and Valsartan reduce myocardial AT1 receptor expression and limit myocardial infarct size in diabetic mice.A Color Segmentation-Based Method to Quantify Atherosclerotic Lesion Compositions with Immunostaining.Diesel exhaust particles impair endothelial progenitor cells, compromise endothelial integrity, reduce neoangiogenesis, and increase atherogenesis in mice.
P2860
Q26785504-BFF61CBF-D2F7-4535-A0C0-809ADFD4F5BAQ28247092-B55CC99A-8D2D-4B0E-85D2-A296501E335FQ30415495-4BADFB9B-A6FD-4F96-B485-45491BE820A4Q33727755-18CA8712-B885-4360-A167-8AABC211E4DBQ34316160-65ED175E-0C9F-40AE-A703-09617669FE3CQ34511040-8744818B-4CE9-4586-89E5-0C393D524760Q34608252-A430EB9D-0907-4038-84B7-B49747B09414Q34905891-9F573F5B-9E8D-439B-B115-152864290350Q35216447-4A4F0D36-0FEE-46DF-8EC7-7DA4B02B180CQ36025434-C7EA90C6-6627-433E-B154-B7B1320035F8Q36239236-93866BF5-760A-4900-ABC6-E911B72F01D5Q36599243-7D6258CC-C7D6-4E48-8856-F7FE888DEA75Q37086076-B3D576EC-EDBA-4DAC-ACCE-E9494423C4E2Q37158159-7747B237-4371-4B95-B48B-0E0A5B2F9F7EQ37314525-3890649B-CF36-4532-A7D9-B9D9E0D700E0Q37510348-5F9024D2-EFA3-4B19-A783-4F810C4DBDACQ37619165-40EBE5A9-E0B2-42AA-A5E7-F5646A64D769Q37648622-AB18AC66-0DE2-4FF1-8F5B-A82B0EFDDC26Q37683440-8E6B9F3C-B945-46B5-AC06-1794297EF472Q37727965-E8C20708-C1CA-447E-8C40-215451174948Q37750291-2262FE0C-99B1-49D6-9C97-86E5930B3A95Q37784830-7AFF472B-CC68-48AC-A4D6-E2257AD51BAAQ37801292-BB043A06-F717-4419-8859-143DF4B6F670Q37859528-D96F4251-8F6A-42DB-A2C2-062816AF9744Q37862922-2A585ADC-CBC1-4D27-8CD4-C361D2081D28Q37871868-F6206299-DB9F-434A-876C-AD454040AC69Q37927098-442C760E-658A-488B-B9B4-ECB691948711Q37939136-6C45F8D6-2C88-4BF7-8549-AF1128B85DF9Q37993917-1F003E35-3E0E-4757-8782-4E67C49E0DEBQ38076124-2D96ABE8-A6AF-48EE-A41D-AB3E0F0FEAD8Q38383375-22B066D5-683D-4414-9198-2113012F7519Q38881790-42CD7345-8722-4675-B9C5-8E2270DABA80Q40067806-2505B103-B755-47A1-9BB8-446B046D75C7Q41922933-D1BB4BC7-577F-4475-A9C1-FD455BC755FAQ43179386-5E4FBE7F-3F9D-4F45-8F46-7D1078D50533Q44623946-BDAC84E7-6385-4AC0-B626-79593F15D435Q45064829-3961A9FB-ED7F-4D8A-9F21-171BC892A0ECQ47350464-9D2A5C81-142B-40FD-A9F3-307E76A40909Q51004437-A48D85DC-14D9-4D68-8377-3047AFA1C5D9Q51069248-47409483-AEDC-40DC-BE35-6B134855FE73
P2860
Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Renin inhibitor aliskiren impr ...... ainst atherosclerotic changes.
@en
Renin inhibitor aliskiren impr ...... ainst atherosclerotic changes.
@nl
type
label
Renin inhibitor aliskiren impr ...... ainst atherosclerotic changes.
@en
Renin inhibitor aliskiren impr ...... ainst atherosclerotic changes.
@nl
prefLabel
Renin inhibitor aliskiren impr ...... ainst atherosclerotic changes.
@en
Renin inhibitor aliskiren impr ...... ainst atherosclerotic changes.
@nl
P2093
P1433
P1476
Renin inhibitor aliskiren impr ...... ainst atherosclerotic changes.
@en
P2093
Akio Kuroi
Hideyuki Ikejima
Hironori Kitabata
Hiroto Tsujioka
Kiyoshi Yoshida
Masami Goto
Seiichi Mochizuki
Shigeho Takarada
Takashi Akasaka
Takashi Tanimoto
P304
P356
10.1161/HYPERTENSIONAHA.108.111120
P407
P577
2008-07-21T00:00:00Z